Literature DB >> 34889418

Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation.

Leslie Skeith1.   

Abstract

There is clinical practice variation in the area of prevention and management of venous thromboembolism (VTE) in pregnancy. There are limited data and differing recommendations across major clinical practice guidelines, especially relating to the role of postpartum low-molecular-weight heparin (LMWH) for patients with mild inherited thrombophilia and those with pregnancy-related VTE risk factors. This chapter explores the issues of practice variation and related data for postpartum VTE prevention. Controversial topics of VTE management in pregnancy are also reviewed and include LMWH dosing and the role of anti-Xa level monitoring, as well as peripartum anticoagulation management around labor and delivery.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34889418      PMCID: PMC8791179          DOI: 10.1182/hematology.2021000291

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  65 in total

1.  The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy.

Authors:  H Marieke Knol; Lejan Schultinge; Nic J G M Veeger; Hanneke C Kluin-Nelemans; Jan J H M Erwich; Karina Meijer
Journal:  Thromb Res       Date:  2012-04-03       Impact factor: 3.944

2.  Pharmacologic Thromboprophylaxis in Obstetrics: Broader Use Demands Better Data.

Authors:  Baha M Sibai; Dwight J Rouse
Journal:  Obstet Gynecol       Date:  2016-10       Impact factor: 7.661

3.  Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study.

Authors:  H S Wik; A F Jacobsen; L Sandvik; P M Sandset
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

4.  Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.

Authors:  Anne Flem Jacobsen; Erik Qvigstad; Per Morten Sandset
Journal:  BJOG       Date:  2003-02       Impact factor: 6.531

5.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Authors:  Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg
Journal:  Blood Adv       Date:  2018-11-27

6.  Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy.

Authors:  Rita Santoro; Piergiorgio Iannaccaro; Simona Prejanò; Gaetano Muleo
Journal:  Blood Coagul Fibrinolysis       Date:  2009-06       Impact factor: 1.276

Review 7.  Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature.

Authors:  E Romualdi; F Dentali; E Rancan; A Squizzato; L Steidl; S Middeldorp; W Ageno
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

8.  The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey.

Authors:  Jennifer Voke; Jane Keidan; Sue Pavord; Neil H Spencer; Beverley J Hunt
Journal:  Br J Haematol       Date:  2007-10-03       Impact factor: 6.998

9.  Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.

Authors:  Mark P Smith; Lucy A Norris; Philip J Steer; Geoffrey F Savidge; John Bonnar
Journal:  Am J Obstet Gynecol       Date:  2004-02       Impact factor: 8.661

10.  Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community.

Authors:  Rachael Hunter; Simon Noble; Sarah Lewis; Paul Bennett
Journal:  BMJ Open       Date:  2019-02-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.